(Q958087)

labetalol (English)

3 October 2016

C₁₉H₂₄N₂O₃

1 reference

labetalol (English)

19 November 2016

CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O

1 reference

medical condition treated

labetalol (English)

19 November 2016

1 reference

14 February 2018

malignant hypertension

1 reference

13 December 2016

myocardial infarction

1 reference

13 December 2016

arterial hypertension

2 references

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

congestive heart failure

1 reference

13 December 2016

1 reference

Food and Drug Administration

13 December 2016

arterial hypertension

start time

3 August 1988

approved by

1 reference

Inxight: Drugs Database

https://drugs.ncats.io/drug/R5H8897N95

2 November 2018

reference URL

http://www.accessdata.fda.gov/drugsatfda_docs/anda/98/74787_Labetalol%20Hydrochloride_Prntlbl.pdf

significant drug interaction

verapamil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

digoxin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

verapamil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

isoflurane

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diltiazem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivastigmine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

methyldopa

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diltiazem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

terazosin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prazosin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

doxazosin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

moxonidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tamsulosin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfuzosin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diltiazem

myocardial depression

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sinoatrial arrest

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

digoxin

toxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

moxonidine

withdrawal hypertension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dronedarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sedation

1 reference

A reference set of clinically relevant adverse drug-drug interactions

xerostomia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

urinary retention

1 reference

A reference set of clinically relevant adverse drug-drug interactions

isoflurane

short coagulation time

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Adrenoceptor alpha 1D

subject has role

antagonist

1 reference

17 August 2016

1 reference

17 August 2016

1 reference

LiverTox likelihood score

17 August 2016

LiverTox toxicity likelihood category C

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Labetalol

15 January 2017

2 references

5 March 2018

MeSH descriptor ID

D007741

15 March 2018

antihypertensive drug

1 reference

15 March 2018

1 reference

MeSH descriptor ID

D007741

adrenergic alpha-1 receptor antagonists

15 March 2018

1 reference

InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)

15 March 2018

Labetalol

0 references

Identifiers

InChI

1 reference

labetalol (English)

19 November 2016

2 references

labetalol (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

36894-69-6

2 references

labetalol (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=36894-69-6

8 April 2021

1 reference

LABETALOL (English)

19 November 2016

2 references

labetalol (English)

19 November 2016

Reaxys registry number

2948416

1 reference

labetalol (English)

3 October 2016

mapping relation type

1 reference

LABETALOL (English)

19 November 2016

mapping relation type

exact match

1 reference

International Chemical Identifier

InChI

InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)

1 reference

LABETALOL (English)

19 November 2016

2 references

inferred from InChIKey

splash10-004i-0319000000-cd3fa186952809ae3558

1 reference

MassBank accession ID

SM818801

0 references

SM818851

0 references

MSBNK-Waters-WA001274

0 references

MSBNK-Waters-WA001275

0 references

MSBNK-Waters-WA001276

0 references

MSBNK-Waters-WA001277

0 references

MSBNK-Waters-WA001278

0 references

MSBNK-Waters-WA001279

0 references

MSBNK-Waters-WA001280

0 references

SPLASH

0 references

splash10-03dl-7900000000-e18d52bcb93357c4a7e2

0 references

HSDB ID

6537

1 reference

Hazardous Substances Data Bank

28 October 2019

LABETALOL (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

1 reference

labetalol (English)

ECHA Substance Infocard ID

19 November 2016

100.048.401

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Labetalol (English)

CAS no.: 36894-69-6 (English)

1 reference

Labetalol (English)

publication date

17 November 2015

1 reference

labetalol (English)

19 November 2016

Labetalol

0 references

0 references

0 references

0 references

1 reference

labetalol (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0014736

2 references

based on heuristic

inferred from InChIKey

2 references

labetalol (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

labetalol (English)

19 November 2016

0 references

1 reference

1 reference

labetalol (English)

3 October 2016

1 reference

Immune Epitope Database and Analysis Resource

labetalol (English)

3 October 2016

1 reference

1 March 2022

0 references

1 reference

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

1 reference

imported from Wikimedia project

1 reference

labetalol (English)

19 November 2016

0 references

WordNet 3.1 Synset ID

03635835-n

1 reference